Led by the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, the GLUCOTYPES project was awarded €4 million in the 2023 EIC Pathfinder Challenge Call,…
Bio-Sourcing is an innovative Belgian biotherapeutic-producing company with a mission to make biotherapeutics available, affordable and sustainable. In the March 2024 round of the EIC Accelerator, Bio-Sourcing was awarded €12.5…
AtG Therapeutics (Barcelona, Spain) is a pre-clinical stage drug development company specialized in the discovery of tumour vulnerabilities and the development of therapeutics and biomarkers to treat advanced cancer. In…
Alentis Therapeutics is a Swiss biotech company on a mission to treat cancer and reverse fibrosis by targeting claudin-1, a key tight junction protein overexpressed in fibrosis and many cancers….
Vandria is a biopharmaceutical company that develops first-in-class mitophagy inducers that rejuvenate cells to treat age-related chronic diseases of the CNS, muscle, lung and liver. Over the past year Catalyze…
Amsterdam UMC spin-off PacingCure develops platform gene transfer technologies for the heart. In the first cut-off of 2022 their project, TRACTION, was awarded the prestigious Transition grant from the European…
Established in 2020, TargED Biopharmaceuticals B.V. (NL) is on a mission to accelerate thrombolysis in all forms of thrombosis – the phenomenon of blood clots blocking veins or arteries. Their…
ENPICOM’s Innovatiekrediet project, “Antibody development module for immunerepertoire sequencing analysis platform”, secured a €500K contribution from Innovatiekrediet towards €1.2M project costs. In the project, ENPICOM leveraged their cloud software solution,…
Achilles Therapeutics (UK) is pushing the frontier of personalized adoptive T cell therapies. In the first round of the 2022 EIC Pathfinder program, an Achilles-led consortium was awarded €4 million…
Metriopharm’s ‘iMPact’ project was awarded a €7.9 million grant from the COVID-19 work programme from Horizon Europe, to clinically validate MP1032, an early intervention treatment against mild-to-moderate COVID-19. Catalyze provided…